Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 8 patents
60 readers on Mendeley
  • Article usage
  • Citations to this article (66)

Advertisement

Research Article Free access | 10.1172/JCI3835

Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses.

B Wizel, M Palmieri, C Mendoza, B Arana, J Sidney, A Sette, and R Tarleton

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Wizel, B. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Palmieri, M. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Mendoza, C. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Arana, B. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Sidney, J. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Sette, A. in: JCI | PubMed | Google Scholar

Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA.

Find articles by Tarleton, R. in: JCI | PubMed | Google Scholar

Published September 1, 1998 - More info

Published in Volume 102, Issue 5 on September 1, 1998
J Clin Invest. 1998;102(5):1062–1071. https://doi.org/10.1172/JCI3835.
© 1998 The American Society for Clinical Investigation
Published September 1, 1998 - Version history
View PDF
Abstract

Experimental models of Chagas' disease, an infection caused by the intracellular protozoan Trypanosoma cruzi, have demonstrated the crucial immunoprotective role played by CD8(+) T lymphocytes. These cells dominate inflammatory foci in parasitized tissues and their elimination from mice leads to uncontrolled parasite replication and subsequent death of the infected host. A trypomastigote surface antigen, TSA-1, and two amastigote surface molecules, ASP-1 and ASP-2, were recently identified as targets of CD8(+) cytotoxic T lymphocytes (CTL) in T. cruzi-infected mice. Until now, however, there was no evidence for the development of parasite-specific CTL in T. cruzi-infected humans. In this study, human CTL specific for TSA-1-, ASP-1-, and ASP-2-derived peptides were detected in the peripheral blood mononuclear cells from 21 of 24 HLA-A2(+) T. cruzi-infected patients. CTL recognition was antigen specific, A2-restricted, and CD8(+) T cell-dependent. Demonstration of human CTL against T. cruzi and against target molecules identified using the murine model provides important information for the optimal design and evaluation of vaccines to prevent or ameliorate Chagas' disease.

Version history
  • Version 1 (September 1, 1998): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (66)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 8 patents
60 readers on Mendeley
See more details